10 Million Additional Mpox Vaccines Available Soon

With the World Health Organization announcing new alerts regarding the mpox virus clade 1 outbreak in African countries and Europe confirming travel-related cases, many governments were concerned about vaccine supply.

To alleviate those concerns, Bavarian Nordic (BN) A/S recently announced an update on plans to produce additional JYNNEOS® (MVA-BN®, IMVAMUNE®) vaccine supplies to tackle the current mpox outbreak.

On August 17, 2024, BN wrote, It would appear that mpox will remain a constant threat to public health, and the company is working closely with the Africa CDC to expand further the manufacturing capacity to produce the mpox vaccine in Africa through transfer of technology to selected African manufacturers.

BN has informed the Africa CDC that, in addition to current orders, it has the capacity to manufacture 10 million doses by the end of 2025 and could already supply up to 2 million doses in 2024.

"We are prepared to work with the Africa CDC and the international community to play our role in protecting and saving lives around the World and to contain the latest outbreak,” said Paul Chaplin, President & CEO of Bavarian Nordic, in a press release.

Since the mpox clade 2 outbreak began in May 2022, BN has supplied more than 15 million doses of the mpox vaccine to more than 76 countries.

While several vaccine efficacy studies have reported JYNNEOS's efficacy against clode 2 between 20% and 80%, studies on clade 1 efficacy are pending. 

In the United States, the JYNNEOS vaccine remains available at specific clinics and pharmacies.